Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Benefits of Sevelamer on Markers of Bone Turnover in Taiwanese Hemodialysis Patients
 
  • Details

Benefits of Sevelamer on Markers of Bone Turnover in Taiwanese Hemodialysis Patients

Journal
Journal of the Formosan Medical Association
Journal Volume
109
Journal Issue
9
Pages
663-672
Date Issued
2010
Author(s)
YU-FENG LIN  
YUNG-MING CHEN  
KUAN-YU HUNG  
TZONG-SHINN CHU  
Kan W.-C.
Huang C.-Y.
SHUEI-LIONG LIN  
Kao T.-W.
JENQ-WEN HUANG  
WEN-CHIH CHIANG  
CHUNG-JEN YEN  
TUN-JUN TSAI  
KWAN-DUN WU  
MING-SHIOU WU  
DOI
10.1016/S0929-6646(10)60107-6
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-78049441696&doi=10.1016%2fS0929-6646%2810%2960107-6&partnerID=40&md5=314d8755491b81aaf24f000e86efec2c
https://scholars.lib.ntu.edu.tw/handle/123456789/516913
Abstract
Background/Purpose: Sevelamer hydrochloride is a recently developed phosphate binder, which is a quaternary amine anion exchanger without calcium or aluminum. Sevelamer is effective in controlling hyperphosphatemia without increasing the calcium load in chronic hemodialysis (HD) patients. We investigated whether sevelamer restored bone metabolism in chronic HD patients. Methods: An 8-week, prospective, open-label, randomized study was conducted after a 2-week washout period in chronic hyperphosphatemic HD patients. This study compared the effect of sevelamer on markers of bone turnover with that of calcium acetate, as stratified by baseline serum intact parathyroid hormone (iPTH) level. Results: There was no difference in the changes of serum phosphorus, calcium-phosphorus product and serum iPTH between the sevelamer and the calcium acetate groups. However, more hypercalcemic events (12%) were documented under calcium acetate treatment. In patients with hypoparathyroidism, calcium acetate treatment decreased serum iPTH at the end of the study, while sevelamer did not. Increased serum alkaline phosphatase levels were found among patients receiving sevelamer treatment compared with those who received calcium acetate treatment. In those patients receiving sevelamer, the serum alkaline phosphatase level was also positively correlated to the sevelamer dosage (r = 0.246, p = 0.013). Conclusion: Sevelamer effectively reduces serum phosphorus with a lower incidence of hypercalcemic effects in HD patients. Sevelamer is an effective means of treatment for chronic hyperphosphatemic HD patients, especially those with hypoparathyroidism. ? 2010 Formosan Medical Association & Elsevier.
SDGs

[SDGs]SDG3

Other Subjects
alkaline phosphatase; aluminum salt; biological marker; calcium acetate; calcium carbonate; calcium phosphate; colecalciferol; parathyroid hormone; phosphorus; sevelamer; vitamin D; acetic acid derivative; alkaline phosphatase; biological marker; calcium acetate; calcium derivative; calcium phosphate; chelating agent; parathyroid hormone; phosphorus; polyamine; sevelamer; adult; alkaline phosphatase blood level; article; blood sampling; bone metabolism; bone turnover; clinical trial; constipation; controlled clinical trial; controlled study; diarrhea; drug capsule; drug dose titration; drug efficacy; drug safety; female; flatulence; gastrointestinal hemorrhage; gastrointestinal symptom; hemodialysis; hemodialysis patient; human; hyperkalemia; hyperphosphatemia; hypoparathyroidism; kidney failure; major clinical study; male; melena; nausea; nervous system; nervous system activity; parathyroid hormone blood level; prospective study; pruritus; randomized controlled trial; side effect; tablet formulation; Taiwan; treatment duration; treatment outcome; treatment response; aged; Asian; blood; bone remodeling; chemically induced disorder; chronic kidney failure; disorders of mineral, electrolyte and metal metabolism; drug effect; hypercalcemia; metabolism; middle aged; renal replacement therapy; Acetates; Adult; Aged; Alkaline Phosphatase; Asian Continental Ancestry Group; Biological Markers; Bone Remodeling; Calcium Compounds; Calcium Phosphates; Chelating Agents; Female; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Phosphorus Metabolism Disorders; Polyamines; Prospective Studies; Renal Dialysis; Treatment Outcome
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science